PMID 19238210 2009 Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
PMID 25311215 2014 Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
PMID 12068308 2002 Mutations of the BRAF gene in human cancer.
PMID 12460919 2002 Missense mutations of the BRAF gene in human lung adenocarcinoma.
PMID 21483012 2011 Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
PMID 23667368 2013 Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group.
PMID 24846033 2014 Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design.
PMID 23562183 2013 Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
PMID 19010912 2008 Genetic predictors of MEK dependence in non-small cell lung cancer.
PMID 22649091 2012 Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
PMID 23833300 2013 Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
PMID 24627688 2014 Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.
rs121913351 in
BRAF gene and
Colorectal Neoplasms
PMID 20350999 2010 Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
PMID 22310681 2012 The road to resistance: EGFR mutation and cetuximab.
PMID 21129611 2010 Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
PMID 12068308 2002 Mutations of the BRAF gene in human cancer.
PMID 19537845 2009 Clinical biomarkers in oncology: focus on colorectal cancer.